OS Therapies Incorporated AI Stock Analysis
Want to see OSTX full AI Analyst Report?
OS Therapies Incorporated (OSTX) AI Stock Analysis
OS Therapies Incorporated
(NYSE MKT:OSTX)
The score is held down primarily by weak financial performance (no revenue, large losses, negative equity, and ongoing cash burn) and a clearly bearish technical trend (below key moving averages with negative MACD). Corporate events modestly offset this through added funding/runway and leadership additions, but valuation support is limited due to negative earnings and no dividend.
OS Therapies Incorporated (OSTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $34.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 718.51K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.38
- Revenue Growth
- ―
- EPS Growth
- -30.21%
- Country
- US
- Employees
- 5
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
OS Therapies Incorporated Business Overview & Revenue Model
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an of...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, OSTX’s ability to generate sustainable operating revenue is typically tied to advancing its drug candidates and monetizing them through one or more of the following mechanisms: (1) out-licensing or partn...
OS Therapies Incorporated Financial Statement Overview
Summary
Financials reflect an early-stage biotech with no revenue, expanding losses, and persistent negative operating and free cash flow. While the most recent periods show no debt (a stabilizer), negative stockholders’ equity and ongoing cash burn increase funding risk and limit flexibility.
Income Statement
5Very NegativeBalance Sheet
12Very NegativeCash Flow
8Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -374.81K | -363.08K | -2,780 | -4,220 | -805 | -1.16M |
| EBITDA | -38.74M | -28.39M | -6.83M | -4.34M | -4.45M | -4.84M |
| Net Income | -39.37M | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
Balance Sheet | ||||||
| Total Assets | 9.90B | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Cash, Cash Equivalents and Short-Term Investments | 205.03M | 269.83K | 5.53M | 38.98K | 171.48K | 80.79K |
| Total Debt | 0 | 0 | 0 | 14.61M | 10.35M | 7.07M |
| Total Liabilities | 20.74B | 12.94M | 4.73M | 24.81M | 18.07M | 11.78M |
| Stockholders Equity | -11.91B | -6.10M | 811.49K | -24.02M | -17.56M | -11.45M |
Cash Flow | ||||||
| Free Cash Flow | -18.53M | -14.24M | -7.28M | -3.01M | -3.79M | -4.41M |
| Operating Cash Flow | -18.53M | -14.24M | -7.28M | -3.01M | -3.79M | -4.40M |
| Investing Cash Flow | 0 | -466.42K | 0 | 1,145 | 230.88K | 200.47K |
| Financing Cash Flow | 15.94M | 9.44M | 12.78M | 2.87M | 3.65M | 3.05M |
OS Therapies Incorporated Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSTX, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.39, and below the 200-day MA of 1.53, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 22.27 is Positive, neither overbought nor oversold. The STOCH value of 24.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSTX.
OS Therapies Incorporated Risk Analysis
OS Therapies Incorporated disclosed 66 risk factors in its most recent earnings report. OS Therapies Incorporated reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksOS Therapies Incorporated Peers Comparison
Overall Rating
ACET54Neutral
ACRV52Neutral
IBIO43Neutral
OSTX41Neutral
ELTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | $26.03M | -0.29 | -69.71% | ― | ― | 57.60% | |
| 52Neutral | $66.94M | -0.85 | -80.87% | ― | ― | 14.08% | |
| 43Neutral | $52.71M | -3.04 | -46.75% | ― | 115.00% | 71.61% | |
| 41Neutral | $38.95M | -0.83 | 1.61% | ― | ― | -30.21% | |
| 39Underperform | $45.01M | -0.87 | -529.69% | ― | ― | 46.62% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OSTX | OS Therapies Incorporated | 0.92 | -0.70 | -43.27% | |
| IBIO | Ibio Inc | 0.85 | -0.15 | -14.77% | |
| XBIT | XBiotech Inc. | 1.73 | -0.49 | -22.07% | |
| ACET | Adicet Bio Inc | 2.50 | -6.74 | -72.94% | |
| ELTX | Elicio Therapeutics, Inc | 1.59 | -6.40 | -80.10% | |
| ACRV | Acrivon Therapeutics, Inc. | 1.56 | -0.70 | -30.97% |
OS Therapies Incorporated Corporate Events
OS Therapies Notes FDA CNPV Program Suspension
PositiveOS Therapies Incorporated’s wholly owned OS Therapies UK Ltd. subsidiary is advancing Herlystic® (OST-HER2), its leading product candidate for prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma.On November 11, 2026...
OS Therapies Announces Warrant Offer to Extend Runway
PositiveOn October 11, 2026, OS Therapies Inc. launched a warrant exercise inducement and exchange offer to a small group of accredited investors, reducing existing warrant exercise prices and issuing equal-sized new five-year warrants at $1.40 per share. Th...
OS Therapies bolsters leadership team amid commercialization push
PositiveEffective September 29, 2026, OS Therapies appointed Francis (Frank) Knuettel II as chief financial officer and Kerry Clem as chief commercial officer, strengthening its executive bench as it transitions from development-stage to commercialization.Th...
OS Therapies Announces Prospectus for Secondary Share Resales
NeutralOn September 10, 2026, OS Therapies Incorporated filed a prospectus supplement with the U.S. Securities and Exchange Commission under its effective Form S-3 shelf registration, covering the potential resale from time to time of up to 5,874,094 shares...
OS Therapies Stockholders Approve Incentive Plan and Board
PositiveOn September 9, 2026, OS Therapies Incorporated stockholders approved an amendment and restatement of the company’s 2023 Incentive Compensation Plan at the 2026 annual meeting, reinforcing its ability to grant equity‑based awards to employees and dir...
OS Therapies Launches $75 Million At-The-Market Offering
PositiveOn August 21, 2026, OS Therapies Incorporated entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market equity offering program, allowing the company to sell up to $75 million of its common stock from time to time th...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
